References
- A. C. Porter and R. R. Vaillancourt, Tyrosine Kinase Receptor-activated Signal Transduction Pathways Which Lead to Oncogenesis, Oncogene, 17, 1343 (1998) https://doi.org/10.1038/sj.onc.1202171
- P. Blume-Jensen and Tony Hunter, Oncogenic Kinase Signalling, Nature, 411, 355 (2001) https://doi.org/10.1038/35077225
- A. Levitzki, Protein Tyrosine Kinase Inhibitors as Therapeutic Agents, Pharmacol. Ther., 82, 231 (1999) https://doi.org/10.1016/S0163-7258(98)00066-7
- R. Tibes, J. Trent, and R. Kurzrock, Tyrosine Kinase Inhibitors and the Dawn of Molecular Cancer Therapeutics, Ann. Rev. Pharmacol. Toxicol., January 6, 2005
- P. Traxler and P. Furet, Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors, Pharmacol. Ther., 82, 195 (1999) https://doi.org/10.1016/S0163-7258(98)00044-8
- D. W. Fry, A. J. Kraker, A. McMichael, L. A. Ambroso, J. M. Nelson, W. R. Leopold, R. W. Connors, and A. J. Bridges, A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, Science, 265, 1093 (1994) https://doi.org/10.1126/science.8066447
- J. Vesel, L. Havlicek, M. Strnad, J. J. Blow, A. Donella-Deana, L. Pinna, D. S. Letham, J.-y. Kato, L. Detkvaud, S. Leclerc, and L. Meijere, Inhibition of Cyclin-dependent Kinases by Purine Analogues, Eur. J. Biochem., 224, 771 (1994) https://doi.org/10.1111/j.1432-1033.1994.00771.x
- E. Weisberg, P. Manley, J. Mestan, S. Cowan-Jacon, A. Ray, and D. Griffin, AMN107 (nilotinib): A Novel and Selective Inhibitor of BCR-ABL. Brit. J. Canver, 94, 1765 (2006) https://doi.org/10.1038/sj.bjc.6603170
- D. Raben, B. A. Helfrich, D. Chan, G. Johnson, and P. A. Bunn, Jr., ZD1839, A Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Alone and in Combination with Radiation and Chemotherapy as a New Therapeutic Strategy in Non-small Cell Lung Cancer, Semin. Oncol., 29 (Supplement 4), 37 (2002) https://doi.org/10.1053/sonc.2002.31521
- R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. M. Clark, P. Santabarbara, and P. Bonomi, Determinants of Tumor Response and Survival with Erlotinib in Patients with Non-Small-Cell Lung Cancer, J. Clin. Oncol., 22, 3238 (2004) https://doi.org/10.1200/JCO.2004.11.057
- Burris H. A. 3rd, Hurwitz H. I., Dees E. C., Dowlati A., Blackwell K. L., O'Neil B., Marcom P. K., Ellis M. J., Overmoyer B., Jones S. F., Harris J. L., Smith D. A., Koch K. M., Stead A., Mangum S., and Spector N. L., Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), A Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients with Metastatic Carcinomas, J Clin. Oncol., 23, 5305 (2005) https://doi.org/10.1200/JCO.2005.16.584
- B. Moy, P. Kirkpatrick, S. Kar, and P. Goss, Lapatinib, Nature Rev. Drug Discov. 6, 431 (2007) https://doi.org/10.1038/nrd2332
- C. C. Price, N. J. Leonard, and D. Y. Curtin, 4-(4'-Diethylamino-1'- methylbutylamino)-7-chloroquinazoline, J. Amer. Chem. Soc. 68, 1305 (1946) https://doi.org/10.1021/ja01211a058
- J. Parrick and R. Ragunathan, Studies of Phthalazine-5,8-quinone, A Ring Contraction, and Some Novel and Potentially Useful Fluorescent Phthalimides, J. Chem. Soc., Perkin Trans. 1, 211 (1993)
- A. J. Bridges, H. Zhou, D. R. Cody, G. W. Rewcastle, A. McMichael, H. D. H. Showalter, D. W. Fry, A. J. Kraker, and W. A. Denny, Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4- (3-Bromoanilino)-6,7-dimethoxyquinazoline (PD153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor, J. Med. Chem., 39, 267 (1996) https://doi.org/10.1021/jm9503613
- O. Tabarrini, V. Cecchetti, A. Fravolini, G. Nocentini, A. Barzi, S. Sabatini, H. Miao, and C. Sissi, Design and Synthesis of Modified Quinolones as Antitumoral Acridones, J. Med. Chem., 42, 2136 (1999) https://doi.org/10.1021/jm980324m